PONLIMSI Biosimilar Approval and Xolair Filings Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA) [Yahoo! Finance]
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) [Yahoo! Finance]
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After A Sharp One Month Share Price Pullback [Yahoo! Finance]
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 [Yahoo! Finance]